BeOne Medicines (ONC) director’s ADS sale tied to RSU tax withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BeOne Medicines Ltd. director Yi Qingqing reported a small share disposition linked to equity compensation. On June 1, 2026, Yi disposed of 235 American Depositary Shares of BeOne Medicines at $279.13 per ADS. According to the disclosure, this sale was carried out under a mandatory tax withholding provision in Yi’s restricted share unit (RSU) agreement in connection with RSU vesting, rather than as a discretionary open-market trade. Following the transactions reported, Yi holds 24,271 Ordinary Shares directly, reflecting a continuing equity stake in the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 235 shares ($65,596)
Net Sell
2 txns
Insider
Yi Qingqing
Role
null
Sold
235 shs ($66K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | American Depositary Shares | 235 | $279.13 | $66K |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 0 shares (Direct, null);
Ordinary Shares — 24,271 shares (Direct, null)
Footnotes (1)
- Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of restricted share units ("RSUs") previously granted to the Reporting Person. The RSUs shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.
Key Figures
ADS sold: 235 ADS
Sale price per ADS: $279.13 per ADS
Ordinary Shares held after: 24,271 Ordinary Shares
+2 more
5 metrics
ADS sold
235 ADS
Disposition on June 1, 2026
Sale price per ADS
$279.13 per ADS
Open-market sale classification
Ordinary Shares held after
24,271 Ordinary Shares
Direct ownership following reported transactions
ADS-to-Ordinary ratio
1 ADS = 13 Ordinary Shares
Relationship between American Depositary Shares and Ordinary Shares
Net buy/sell shares
-235 shares
Net share change across reported transactions
Key Terms
American Depositary Shares, restricted share units, mandatory tax withholding provision, change in control, +1 more
5 terms
mandatory tax withholding provision financial
"The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement"
change in control financial
"Unvested securities are subject to accelerated vesting upon a change in control or certain termination events."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
accelerated vesting financial
"Unvested securities are subject to accelerated vesting upon a change in control or certain termination events."
FAQ
What insider transaction did BeOne Medicines (ONC) director Yi Qingqing report?
Director Yi Qingqing reported disposing of 235 American Depositary Shares of BeOne Medicines Ltd. at $279.13 per ADS. The filing describes this as a mandatory tax-related sale connected to the vesting of previously granted restricted share units.
How many BeOne Medicines (ONC) ADS did the director dispose of and at what price?
Yi Qingqing disposed of 235 American Depositary Shares of BeOne Medicines Ltd. at a reported price of $279.13 per ADS. The transaction is classified as a sale, but the accompanying footnote highlights its role in satisfying tax withholding requirements.
What BeOne Medicines (ONC) holdings does Yi Qingqing report after this Form 4 filing?
After the reported transactions, Yi lists 24,271 Ordinary Shares of BeOne Medicines Ltd. held directly. The Form 4 shows zero ADS remaining, but the Ordinary Share position indicates an ongoing ownership interest in the company’s equity.
What vesting terms apply to Yi Qingqing’s BeOne Medicines (ONC) RSUs?
Yi’s restricted share units become fully vested on the earlier of the first anniversary of the grant date or the next annual general meeting. Vesting stops if Yi ceases serving as a director, with provisions for accelerated vesting upon a change in control or certain termination events.